Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
 |
|
Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.
Markers of inflammation in woman on different hormone replacement therapies.
Ann. Med. 35, 353-361 (2003)
BACKGROUND AND AIM. To measure in ̄ammatory markers
in postmenopausal women on different forms of hormone
in postmenopausal women on different forms of hormone
replacement therapy (HRT).
replacement therapy (HRT).
METHOD. C-reactive protein (CRP), ®brinogen, plasma
METHOD. C-reactive protein (CRP), ®brinogen, plasma
viscosity (PV), albumin and white blood cell (WBC) count
viscosity (PV), albumin and white blood cell (WBC) count
were determined in 749 postmenopausal women.
were determined in 749 postmenopausal women.
RESULTS. CRP concentration was signi®cantly higher in
RESULTS. CRP concentration was signi®cantly higher in
women on estrogen monotherapy (difference of the median
women on estrogen monotherapy (difference of the median
(d) 0.96
(d) 0.96 mg/l,
mg/l,
P
P
=
= 0.013), compared to those without HRT,
0.013), compared to those without HRT,
but there was no difference in women on combined HRT.
but there was no difference in women on combined HRT.
Fibrinogen concentration was signi®cantly lower in women
Fibrinogen concentration was signi®cantly lower in women
on estrogen monotherapy (d 0.25
on estrogen monotherapy (d 0.25 g/l,
g/l,
P
P
=
= 0.004) and
0.004) and
combined HRT (d 0.4
combined HRT (d 0.4 g/l,
g/l,
P
P
<
< 0.001), compared to women
0.001), compared to women
without HRT. Similarly, PV was signi®cantly lower in women
without HRT. Similarly, PV was signi®cantly lower in women
on estrogen monotherapy (d 0.017
on estrogen monotherapy (d 0.017 mPa
mPa
⋅
⋅
s,
s,
P
P
=
= 0.007) and
0.007) and
women on combined HRT (d 0.039
women on combined HRT (d 0.039 mPa
mPa
⋅
⋅
s,
s,
P
P
<
< 0.001),
0.001),
compared to those without HRT. No differences were found
compared to those without HRT. No differences were found
for WBC count and the negative acute phase marker
for WBC count and the negative acute phase marker
albumin in the various treatment groups. In contrast to
albumin in the various treatment groups. In contrast to
oral estrogen administration, levels o fCRP, ®brinogen and
oral estrogen administration, levels o fCRP, ®brinogen and
PV in women on transdermal estrogen therapy did not differ
PV in women on transdermal estrogen therapy did not differ
from the no-HRT group. There was no association between
from the no-HRT group. There was no association between
these markers o fin ̄ammation and plasma estrogen levels.
these markers o fin ̄ammation and plasma estrogen levels.
CONCLUSION. Oral estrogen monotherapy was associated
CONCLUSION. Oral estrogen monotherapy was associated
with highest concentrations o fCRP. In contrast, other
with highest concentrations o fCRP. In contrast, other
markers o fin ̄ammation were either similar or lower in the
markers o fin ̄ammation were either similar or lower in the
oral HRT group, compared to the group o fwomen without
oral HRT group, compared to the group o fwomen without
HRT, suggesting that higher CRP concentrations re ̄ect
HRT, suggesting that higher CRP concentrations re ̄ect
estrogen effects on CRP expression rather than a systemic
estrogen effects on CRP expression rather than a systemic
pro-in ̄ammatory effect.
pro-in ̄ammatory ef
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
coronary disease; C-reactive protein; fibrinogen; hormone; replacement therapy; inflammation; plasma viscosity
ISSN (print) / ISBN
0785-3890
e-ISSN
1365-2060
Journal
Annals of Medicine
Quellenangaben
Volume: 35,
Pages: 353-361
Publisher
Informa Healthcare
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Health Economics and Health Care Management (IGM)
Institute of Epidemiology (EPI)
Institute of Epidemiology (EPI)